Farmacoriflessioni
Cannabis ed epilessia in Pediatria: mito o realtà?
Cannabis and epilepsy: myth or reality?
Cristina Forest, Elisa Fiumana, Raffaella Faggioli, Agnese Suppiej, Giuseppe Maggiore
Scuola di Specializzazione in Pediatria, Dipartimento di Scienze Mediche dell’Università di Ferrara, Sezione di Pediatria, Azienda Ospedaliera Universitaria di Ferrara
Maggio 2019 - pagg. 303 -309
Abstract
In recent years, there has been an increasing interest for the use of medical Cannabis in
Paediatrics. Several pharmacological properties are attributed to Cannabis by preclinical
studies, but the most important application is related to the treatment of drug-resistant epilepsy.
The aim of this paper is to review the preclinical data on cannabidiol, one of the
most popular cannabinoids, and to discuss the recent clinical trial published in the New
England Journal of Medicine that led the US Food and Drug Administration to approve a
drug derived from marijuana for treating two rare and severe forms of epilepsy: the Dravet
syndrome and the Lennox-Gastaut syndrome.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Zou S, Kumar U. Cannabinoid receptors
and the endocannabinoid system: signaling
and function in the central nervous system.
Int J Mol Sci 2018;19(3).
2. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid
signaling at the periphery: 50
years after THC. Trends Pharmacol Sci
2015;36(5):277-96.
3. Russo, EB. Beyond Cannabis: plants and
the endocannabinoid system. Trends Pharmacol
Sci 2016;37(7):594-605.
4. Campbell CT, Shaw Phillips M, Manasco
K. Cannabinoids in Pediatrics. J Pediatr
Pharmacol Ther 2017;22(3):176-185.
5. Lega Italiana contro l’Epilessia (LICE).
Gruppo per la Cannabis terapeutica. https://
www.lice.it/LICE_ita/gruppi/cannabis/
componenti.php.
6. Pisanti S, Malfitano AM, Ciaglia E, et al.
Cannabidiol: state of the art and new challenges
for therapeutic applications. Pharmacol
Ther 2017;175:133-50.
7. Renard J, Rushlow WJ, Laviolette SR. Effects
of adolescent THC exposure on the prefrontal
GABAergic system: implications for
schizophrenia-related psychopathology.
Front Psychiatry 2018;9:281.
8. Tai S, Fantegrossi WE. Pharmacological
and toxicological effects of synthetic cannabinoids
and their metabolites. Curr Top Behav
Neurosci 2017;32:249-62.
9. Gaston TE, Bebin EM, Cutter GR, Liu Y,
Szaflarski JP; UAB CBD Program. Interactions
between cannabidiol and commonly
used antiepileptic drugs. Epilepsia
2017;58(9):1586-92.
10. Michelucci R, La Neve A, Mecarelli O, et
al. Guida pratica per la gestione del paziente
affetto da epilessia. Documento congiunto LICE-
SIMG.
11. Suraev A, Lintzeris N, Stuart J, et al. Composition
and use of Cannabis extracts for
childhood epilepsy in the Australian community.
Scientific Reports 2018;8:10154.
12. Brunklaus A, Zuberi SM. Dravet syndrome
- from epileptic encephalopathy to channelopathy.
Epilepsia 2014;55(7):979-84.
13. Gupta S. Weed: a dr Sanjay Gupta investigation.
CNN, August 11, 2013.
14. Maa E, Figi P. The case for medical marijuana
in epilepsy. Epilepsia 2014;55(6):783-6.
15. Let’s weed. https://www.letsweed.com/
press-review.
16. Friedman D, Devinsky O. Cannabinoids
in the treatment of epilepsy. N Engl J Med
2015;373(11):1048-58.
17. Gloss D, Vickrey B. Cannabinoids for epilepsy
(review). Cochrane Database Syst Rev
2014;3:CD009270.
18. Devinsky O, Cross JH, Laux L, et al. Trial
of cannabidiol for drug-resistant seizures in
the Dravet syndrome. N Engl J Med 2017;
376:2011-20.
19. Devinsky O, A. Patel A, Cross JH, et al.
Effect of cannabidiol on drop seizures in the
Lennox-Gastaut syndrome. N Engl J Med
2018;378:1888-97.
20. Bourgeois BF, Douglass LM, Sankar R.
Lennox-Gastaut syndrome: a consensus approach
to differential diagnosis. Epilepsia
2014;55:4-9.
21. AAVV. Raccomandazioni per il medico
prescrittore di sostanza vegetale Cannabis
FM2 infiorescenze. Documento approvato
dal Gruppo di lavoro previsto dall’Accordo di
collaborazione del Ministero della Salute e
del Ministero della Difesa del 18 settembre
2014. Febbraio 2017. http://www.salute.
gov.it/imgs/C_17_pagineAree_4589_listaFile_
itemName_2_file.pdf
22. Ministero della Salute. Uso medico della
Cannabis. http://www.salute.gov.it/portale/
temi/p2_6.jsp?lingua=italiano&id=4587&area
=sostanzeStupefacenti&menu=vuoto.
23. Ministero della Salute. Prescrizione di
preparazioni magistrali a base di Cannabis.
http://www.salute.gov.it/portale/temi/p2_6.
jsp?lingua=italiano&id=4589&area=sostanze-
Stupefacenti&menu=organismo.
24. Wilkinson JD, Whalley BJ, Baker D, et al.
Medicinal Cannabis: is delta9-tetrahydrocannabinol
necessary for all its effects? J Pharm
Pharmacol 2003;55(12):1687-94.
Corrispondenza: cristina.forest88@gmail.com